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Results: PCSK9 dose-dependently reduced LDLR expression in control
and FH fibroblasts to similar extents, by up to 77±8% and 82±7%. Likewise,
PCSK9 reduced LDLR abundance by 39±8% in non-FH and by 45±10% in
HeFH lymphocytes, irrespective of their LDLR mutation status. We found
positive correlations of the same magnitude between PCSK9 and LDL-C in
controls (b=0·22, p=0·0003), D206E (b=0·20, p=0·0002), V408M (b=0·24,
p=0·0002), and D154N (b=0·25, p=0·048) HeFH patients. The strengths of
these associations were all similar.
Conclusion: Elevated PCSK9 levels are equally detrimental for HeFH and
non-FH patients: a 100ng/mL increase in PCSK9 will lead to an increase in
LDL-C of 0·20-0·25mmol/L in controls and HeFH alike, irrespective of their
LDLR mutation. This explains why non-FH and HeFH patients respond
equally well to monoclonal antibodies targeting PCSK9.
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Introduction: Paraoxonase 1 (PON1) is an esterase synthesized by the
liver and secreted into the plasma, where it is associated with high density
lipoproteins (HDL). Its role is to protect LDL and HDL from oxidation, thus
preventing atherosclerosis. A decreased level of plasma PON1 activities has
been found in diabetes mellitus, cardiovascular disorders and chronic liver dis-
eases; but, it can also be influenced by diet and life-style. The purpose of this
study was to assess the PON1 activities in the insulin-resistant rats fed with a
fructose-enriched diet, in the presence and in the absence of an antioxidant
treatment with alpha-lipoic acid (AL).
Methods: 48 male Sprague-Dawley rats were randomized into two series:
rats fed for 3 months with standard chow (Control) or with standard chow sup-
plemented with fructose (60%). In each series, a group of rats was treated
intraperitoneally during 14 days/month with NaCl 0.9% and another group
with 50 mg/kg/day AL. At the end of the 3 months, we assessed: 1) peripheral
tissue resistance to insulin (HOMA-IR) and plasma lipid profile, 2) paraox-
onase, arylesterase and lactonase activities of PON1, 3) plasma homocysteine
(Hcy) level and 4) hepatic transaminase activities: aspartate-aminotransferase
and alanine-aminotransferase.
Results: The fructose intake increased peripheral tissue resistance to insulin
(HOMA-IR) and plasma lipoprotein level, less the HDL. Also, transaminase and
PON1 activities, especially arylesterase and lactonase activities, and the plasma
Hcy level were significantly (p>0.05) enhanced in the fructose group. The AL dis-
continuous treatment associated with the fructose-enriched diet improved the
tissue sensitivity to insulin and decreased the plasma lipoprotein levels. Moreover,
the AL treatment restored PON1 and transaminase activities, without influencing
the Hcy concentration. A decrease in plasma transaminase activities was noted
even when AL was associated with standard diet.
Conclusions: In our experimental conditions, the fructose intake induced
an increase in plasma transaminase and PON1 activities in association with a
Hyperhomocysteinemia. The AL treatment restored the enzymes’ activities
and had a hepatoprotective effect, but without influence on Hcy level.
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Aim: Tea is one of the most consumed beverages in the world and its health-
promoting effects have been widely investigated.Lipid-lowering effects of pu-erh
tea have attracted growing interest.The importance of liver in lipid metabolism
prompted us to investigate the lipid-lowering properties of pu-erh tea in rat pri-
mary culture hepatocytes.We tested the effect of a Hao Ling pu-erh tea extract
(HLPT) and one of the major components of tea as Epigallocatechin-3-gallate
(EGCG) which is largely recognized as a hypolipidemic molecule.
Methods: HLPT: an infusion of Hao Ling pu-erh tea was lyophilized and
quantified for its composition in catechins by LC-MS. 24h after seeding on
collagen, rat hepatocytes in primary culture were treated for 24h with various
concentrations of HLPT(100,200,400,600 μg/ml) and EGCG(30,100 uM) and
compared to CyclosporinA (hyperlipidemic reference) and Clofibrate (hypo-
lipidemic drug used in human)(n=3 in triplicate).Lipid droplet accumulation
was measured by LipidTox staining and evaluated by fluorescence microscopy
on an ArrayScanXTI high Content Analysis Reader(Cellomics Inc.).
Results: We found that HLPT significantly prevented hepatocyte lipid
accumulation (-56%) and in the same proportion to Clofibrate.EGCG also sig-
nificantly attenuated lipid accumulation (-19%) but less than HLPT.
Conclusion: The main result of this study was to point out the major implica-
tion of liver cells in the hypolipidemic effects of HLPT.Moreover, we have shown
here that this effect was partly due to the EGCG, well known for its antioxidant
effects.However as we reported here that HLPT has a higher hypolipidemic effect
than EGCG alone, which means that EGCG acts in synergy with other HLPT
components such as theaflavins but this hypothesis has to be confirmed in further
experiments.In future, the variation of expression of genes involved in lipid metab-
olism (THRSP,LXR,PPar-α) by qPCR induced by HLPT will allow us to improve
the understanding of the effect induced by HLPT.
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Objective: Epoxyeicosatrienoic acids (EETs) are synthesized from arachi-
donic acid, notably in endothelial cells, and display attractive metabolic, vaso-
dilatory and anti-inflammatory properties. We demonstrated previously that
inhibiting EET degradation mediated by soluble epoxide hydrolase (sEH)
reduces hypertension and heart failure, and others reported that it improves
glucose homeostasis in type 2 diabetes. However, the impact of such strategy
on target organ damage in diabetes remains to be clarified.
Materials and methods: The pharmacological sEH inhibitor t-AUCB
(10 mg/l in drinking water) was administered for 8 weeks in mice subjected to a
high-fat diet (HFD, 60% fat) for 16 weeks. Mice on control chow diet (10% fat),
non-treated HFD mice and HFD mice treated with glibenclamide (80 mg/l) served
as controls.
Results: Glibenclamide and t-AUCB similarly prevented the increased fasting
glycemia in HFD mice (Control: 5.4±0.2; HFD: 8.0±0.8; HFD+GLI: 5.1±0.3;
HFD+t-AUCB: 5.6±0.2 mmol/L; p<0.05). However, only t-AUCB improved glu-
cose tolerance and decreased gluconeogenesis. In parallel, t-AUCB prevented adi-
pose tissue activation and dyslipidemia. Moreover, t-AUCB improved coronary
endothelial function and prevented diastolic dysfunction, as shown by echocar-
diography (E/A ratio; Control: 1.25±0.02; HFD: 1.05±0.03; HFD+GLI:
1.07±0.04; HFD+t-AUCB: 1.23±0.04; p<0.05) and invasive hemodynamics
(LVEDPVR; Control: 1.9±0.55; HFD: 3.8±0.61; HFD+GLI: 3.1±0.8; HFD+t-
AUCB: 1.88±0.2 mmHg/RVU; p<0.05). Finally, t-AUCB prevented the increased
urinary albumine-to-creatinine ratio and decreased renal inflammation.
Discussion: These results demonstrate that beyond its glucose-lowering
effects sEH inhibition improves coronary endothelial function, diastolic dys-
function and prevents early kidney damage in a murine model of type 2 dia-
betes. This positive impact on target organ damage and metabolic
homeostasis prompts sEH inhibition as a promising therapeutic perspective
in type 2 diabetes.
